related documents
- An assessment of safety of daily subcutaneous (SC) injections of kineret (TM) (anakinra-recombinant interleukin-1 receptor antagonist) in a standard practice population of patients with rheumatoid arthritis (RA) Conferences
- Assessment of changes in patient function, measured by the health assessment questionnaire - Disability index (HAQ-DI), following daily subcutaneous (SC) injections of kineret (TM) (anakinra-recombinant interleukin-1 receptor antagonist) in a standard practice population of patents with rheumatoid arthritis (RA) Conferences
- Frequency and characteristics of autoantibodies in rheumatoid arthritis (RA) and their relationship to disease duration: Results of two large Etanercept trials Conferences
- Long-term tolerability of the bisphosphonates in postmenopausal osteoporosis: A comparative review Conferences
- Measuring disease activity in systemic onset JIA Conferences
- Nonvertebral fracture risk is significantly reduced with risedronate treatment in just one year Conferences
- Once-a-week risedronate is effective in reducing vertebral fracture risk Conferences